These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

130 related articles for article (PubMed ID: 35195692)

  • 1. HIV-1-RNA and total HIV-1-DNA loads in the genital compartment in men receiving dolutegravir- versus darunavir-based combined ART (cART) regimens during primary HIV infection.
    Mariaggi AA; Bauer R; Charre C; Gardiennet E; Meiffredy V; Ajana F; Lacombe K; Pialoux G; Cua E; Rouzioux C; Meyer L; Cheret A; Avettand-Fenoel V
    J Antimicrob Chemother; 2022 Feb; 77(3):735-739. PubMed ID: 35195692
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Once-daily dolutegravir versus darunavir plus cobicistat in adults at the time of primary HIV-1 infection: the OPTIPRIM2-ANRS 169 randomized, open-label, Phase 3 trial.
    Chéret A; Bauer R; Meiffrédy V; Lopez P; Ajana F; Lacombe K; Morlat P; Lascoux C; Reynes J; Calin R; Abel S; Goujard C; Rouzioux C; Avettand-Fenoel V; Meyer L
    J Antimicrob Chemother; 2022 Aug; 77(9):2506-2515. PubMed ID: 35762503
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Bictegravir versus dolutegravir, each with emtricitabine and tenofovir alafenamide, for initial treatment of HIV-1 infection: a randomised, double-blind, phase 2 trial.
    Sax PE; DeJesus E; Crofoot G; Ward D; Benson P; Dretler R; Mills A; Brinson C; Peloquin J; Wei X; White K; Cheng A; Martin H; Quirk E
    Lancet HIV; 2017 Apr; 4(4):e154-e160. PubMed ID: 28219610
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Decay kinetics of HIV-1-RNA in seminal plasma with dolutegravir/lamivudine versus dolutegravir plus emtricitabine/tenofovir alafenamide in treatment-naive people living with HIV.
    Saborido-Alconchel A; Serna-Gallego A; Lopez-Cortes LE; Trujillo-Rodriguez M; Praena-Fernandez JM; Dominguez-Macias M; Lozano C; Muñoz-Muela E; Espinosa N; Roca-Oporto C; Sotomayor C; Herrero M; Gutierrez-Valencia A; Lopez-Cortes LF
    J Antimicrob Chemother; 2023 Sep; 78(9):2354-2360. PubMed ID: 37545387
    [TBL] [Abstract][Full Text] [Related]  

  • 5. HIV-DNA decrease during treatment in primary HIV-1 infection with three different drug regimens: Italian Network of Acute HIV Infection (INACTION) clinical trial.
    Bruzzesi E; Gabrieli A; Bernasconi D; Marchetti G; Calcagno A; Ripamonti D; Antinori A; Squillace N; Cingolani A; Muscatello A; Bandera A; Gori A; Rusconi S; Nozza S;
    J Med Virol; 2023 Sep; 95(9):e29114. PubMed ID: 37752816
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Plasma, intracellular and lymph node antiretroviral concentrations and HIV DNA change during primary HIV infection: Results from the INACTION P25 study.
    De Nicolò A; Palermiti A; Dispinseri S; Marchetti G; Trunfio M; De Vivo E; D'Avolio A; Muscatello A; Gori A; Rusconi S; Bruzzesi E; Gabrieli A; Bernasconi DP; Bandera A; Nozza S; Calcagno A;
    Int J Antimicrob Agents; 2024 Aug; 64(2):107200. PubMed ID: 38768738
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Coformulated bictegravir, emtricitabine, and tenofovir alafenamide versus dolutegravir with emtricitabine and tenofovir alafenamide, for initial treatment of HIV-1 infection (GS-US-380-1490): a randomised, double-blind, multicentre, phase 3, non-inferiority trial.
    Sax PE; Pozniak A; Montes ML; Koenig E; DeJesus E; Stellbrink HJ; Antinori A; Workowski K; Slim J; Reynes J; Garner W; Custodio J; White K; SenGupta D; Cheng A; Quirk E
    Lancet; 2017 Nov; 390(10107):2073-2082. PubMed ID: 28867499
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Efficacy and safety of switching to dolutegravir plus emtricitabine/tenofovir disoproxil fumarate (TDF) or elvitegravir/cobicistat/emtricitabine/TDF in virologically suppressed HIV-infected patients in clinical practice: results from a multicentre, observational study.
    Baldin G; Ciccullo A; Capetti A; Rusconi S; Sterrantino G; Cossu MV; Giacomelli A; Lagi F; Latini A; Bagella P; De Luca A; Di Giambenedetto S; Madeddu G
    HIV Med; 2019 Feb; 20(2):164-168. PubMed ID: 30457197
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Dolutegravir with emtricitabine and tenofovir alafenamide or tenofovir disoproxil fumarate versus efavirenz, emtricitabine, and tenofovir disoproxil fumarate for initial treatment of HIV-1 infection (ADVANCE): week 96 results from a randomised, phase 3, non-inferiority trial.
    Venter WDF; Sokhela S; Simmons B; Moorhouse M; Fairlie L; Mashabane N; Serenata C; Akpomiemie G; Masenya M; Qavi A; Chandiwana N; McCann K; Norris S; Chersich M; Maartens G; Lalla-Edward S; Vos A; Clayden P; Abrams E; Arulappan N; Hill A
    Lancet HIV; 2020 Oct; 7(10):e666-e676. PubMed ID: 33010240
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Fixed-dose combination bictegravir, emtricitabine, and tenofovir alafenamide versus dolutegravir-containing regimens for initial treatment of HIV-1 infection: week 144 results from two randomised, double-blind, multicentre, phase 3, non-inferiority trials.
    Orkin C; DeJesus E; Sax PE; Arribas JR; Gupta SK; Martorell C; Stephens JL; Stellbrink HJ; Wohl D; Maggiolo F; Thompson MA; Podzamczer D; Hagins D; Flamm JA; Brinson C; Clarke A; Huang H; Acosta R; Brainard DM; Collins SE; Martin H; ;
    Lancet HIV; 2020 Jun; 7(6):e389-e400. PubMed ID: 32504574
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Dolutegravir or Darunavir in Combination with Zidovudine or Tenofovir to Treat HIV.
    Paton NI; Musaazi J; Kityo C; Walimbwa S; Hoppe A; Balyegisawa A; Kaimal A; Mirembe G; Tukamushabe P; Ategeka G; Hakim J; Mugerwa H; Siika A; Asienzo J; Castelnuovo B; Kiragga A; Kambugu A;
    N Engl J Med; 2021 Jul; 385(4):330-341. PubMed ID: 34289276
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Pharmacovirological analyses of blood and male genital compartment in patients receiving dolutegravir + lamivudine dual therapy as a switch strategy (ANRS 167 LAMIDOL trial).
    Charpentier C; Peytavin G; Raffi F; Burdet C; Landman R; Lê MP; Katlama C; Collin G; Benalycherif A; Cabie A; Mentré F; Yazdanpanah Y; Descamps D; Joly V
    J Antimicrob Chemother; 2020 Jun; 75(6):1611-1617. PubMed ID: 32091102
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Switching to fixed-dose bictegravir, emtricitabine, and tenofovir alafenamide from dolutegravir plus abacavir and lamivudine in virologically suppressed adults with HIV-1: 48 week results of a randomised, double-blind, multicentre, active-controlled, phase 3, non-inferiority trial.
    Molina JM; Ward D; Brar I; Mills A; Stellbrink HJ; López-Cortés L; Ruane P; Podzamczer D; Brinson C; Custodio J; Liu H; Andreatta K; Martin H; Cheng A; Quirk E
    Lancet HIV; 2018 Jul; 5(7):e357-e365. PubMed ID: 29925489
    [TBL] [Abstract][Full Text] [Related]  

  • 14. First case of Dolutegravir and Darunavir/r multi drug-resistant HIV-1 in Cameroon following exposure to Raltegravir: lessons and implications in the era of transition to Dolutegravir-based regimens.
    Fokam J; Takou D; Semengue ENJ; Teto G; Beloumou G; Dambaya B; Santoro MM; Mossiang L; Billong SC; Cham F; Sosso SM; Temgoua ES; Nanfack AJ; Moudourou S; Kamgaing N; Kamgaing R; Ngako Pamen JN; Etame MMN; Bissek AZ; Elat JN; Moussi EE; Colizzi V; Perno CF; Ndjolo A;
    Antimicrob Resist Infect Control; 2020 Aug; 9(1):143. PubMed ID: 32843050
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Co-formulated bictegravir, emtricitabine, and tenofovir alafenamide versus dolutegravir with emtricitabine and tenofovir alafenamide for initial treatment of HIV-1 infection: week 96 results from a randomised, double-blind, multicentre, phase 3, non-inferiority trial.
    Stellbrink HJ; Arribas JR; Stephens JL; Albrecht H; Sax PE; Maggiolo F; Creticos C; Martorell CT; Wei X; Acosta R; Collins SE; Brainard D; Martin H
    Lancet HIV; 2019 Jun; 6(6):e364-e372. PubMed ID: 31068272
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Virological and immunological impact of integrase inhibitor-based regimens initiated during primary HIV-1 infection.
    Veil R; Poizot-Martin I; Reynes J; Goujard C; Seng R; Delobel P; Cotte L; Duvivier C; Rey D; Tran L; Surgers L; Allavena C; Lascoux Combe C; Cheret A; Meyer L
    AIDS; 2020 Mar; 34(4):493-500. PubMed ID: 31764069
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Brief Report: Virologic Response by Baseline Viral Load With Dolutegravir Plus Lamivudine vs Dolutegravir Plus Tenofovir Disoproxil Fumarate/Emtricitabine: Pooled Analysis.
    Eron J; Hung CC; Baril JG; Slim J; Falcó V; Bogner J; Maggiolo F; Mills A; Sievers J; Man CY; Urbaityte R; Underwood M; Tenorio AR; Pappa KA; Wynne B; Koteff J; Gartland M; Smith KY; Aboud M
    J Acquir Immune Defic Syndr; 2020 May; 84(1):60-65. PubMed ID: 31977595
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Virologic Failure Among People Living With HIV Initiating Dolutegravir-Based Versus Other Recommended Regimens in Real-World Clinical Care Settings.
    Nance RM; Vannappagari V; Smith K; Johannes CB; Calingaert B; Saltus CW; Mayer KH; Whitney BM; Rodriguez B; Moore RD; Eron JJ; Geng E; Mathews WC; Mugavero MJ; Saag MS; Kitahata MM; Delaney JAC; Crane HM
    J Acquir Immune Defic Syndr; 2019 Aug; 81(5):572-577. PubMed ID: 31107299
    [TBL] [Abstract][Full Text] [Related]  

  • 19. HIV-1 RNA Kinetics in Blood Plasma and in Seminal Plasma of Men Starting a Dolutegravir-Based Triple-Combination Regimen at the Time of Primary HIV-1 Infection.
    Ghosn J; Assoumou L; Lascoux-Combe C; Peytavin G; Amat K; Gabassi A; Le MP; Nzalakanda R; Valin N; Landman R; Chaix ML; Delaugerre C
    J Infect Dis; 2022 Jan; 225(1):116-120. PubMed ID: 34166492
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Dolutegravir plus lamivudine versus dolutegravir plus tenofovir disoproxil fumarate and emtricitabine in antiretroviral-naive adults with HIV-1 infection (GEMINI-1 and GEMINI-2): week 48 results from two multicentre, double-blind, randomised, non-inferiority, phase 3 trials.
    Cahn P; Madero JS; Arribas JR; Antinori A; Ortiz R; Clarke AE; Hung CC; Rockstroh JK; Girard PM; Sievers J; Man C; Currie A; Underwood M; Tenorio AR; Pappa K; Wynne B; Fettiplace A; Gartland M; Aboud M; Smith K;
    Lancet; 2019 Jan; 393(10167):143-155. PubMed ID: 30420123
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.